Precigen
PGEN | NASDAQ
$4.30
-$0.24 (-5.29%)
At close: Nov 16, 2026, 4:00 PM ET
$4.33
+$0.03 (+0.70%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Precigen Company Profile
Company profile explainedCompany Profile
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
Key Executives
| Name | Position |
|---|---|
| Helen Sabzevari | President, Chief Executive Officer & Director |
| Donald Lehr | Chief Legal Officer & Corporate Secretary |
| Harry Thomasian Jr. | Chief Financial Officer |
| Rutul R. Shah | Chief Operating Officer |
| Amy R. Lankford | Senior Vice President & Head of Clinical Operations and Regulatory Affairs |
| Bryan T. Butman | Senior Vice President & Head of CMC |
| Douglas E. Brough | Senior Vice President & Head of Research |
| Phil Tennant | Chief Commercial Officer |
| Randal J. Kirk | Executive Chairman |
| Steven Harasym | Vice President & Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 24, 2026 | 4 | Filing |
| Aug 28, 2026 | 4 | Filing |
| Aug 25, 2026 | 4 | Filing |
| Aug 25, 2026 | 4 | Filing |
| Aug 25, 2026 | 4 | Filing |
| Aug 25, 2026 | 4 | Filing |
| Aug 25, 2026 | 4 | Filing |
| Aug 25, 2026 | 4 | Filing |
| Aug 07, 2026 | 4 | Filing |
| Aug 07, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Precigen
| Country | United States |
| IPO Date | Aug 8, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 160 |
| CEO | Helen Sabzevari |
Contact Details
20374 Seneca Meadows Parkway Germantown,
Maryland 20876 United States
Stock Details
| Ticker Symbol | PGEN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001356090 |
| CUSIP Number | 74017N105 |
| ISIN Number | US74017N1054 |
| SIC Code | 2834 |
Recent News
- 8 days ago / zacks.comWhat Makes Precigen (PGEN) a New Buy Stock
- 8 days ago / zacks.comPGEN Q3 Earnings Call Highlights Launch Momentum and Competition
- 12 days ago / seekingalpha.comPrecigen, Inc. (PGEN) Q3 2026 Earnings Call Transcript
- 12 days ago / marketbeat.comWhat Precigen (PGEN) Said on Its Q3 Earnings Call
- 12 days ago / zacks.comPrecigen, Inc. (PGEN) Q3 Earnings and Revenues Miss Estimates
- 12 days ago / prnewswire.comPrecigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance
- 15 days ago / zacks.comPrecigen Gears Up to Report Q3 Earnings: What Can Investors Expect?
- 19 days ago / prnewswire.comPrecigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4
- 1 month ago / zacks.comPGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know
- 2 months ago / zacks.comPrecigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?
Add to Watchlist
Select watchlists to add or remove PGEN